Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,950 INR | -1.91% |
|
-6.22% | +1.91% |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales 1 | 124.2 | 188.1 | 247.2 | 451.3 |
EBITDA 1 | 10.42 | 13.38 | 43.16 | 111.4 |
EBIT 1 | 9.357 | 11.63 | 41.62 | 106.7 |
Operating Margin | 7.53% | 6.18% | 16.84% | 23.64% |
Earnings before Tax (EBT) 1 | 10.94 | 13.58 | 45.49 | 114.1 |
Net income 1 | 8.116 | 10.26 | 33.86 | 85.03 |
Net margin | 6.54% | 5.45% | 13.7% | 18.84% |
EPS 2 | 2.029 | 2.564 | 8.464 | 20.82 |
Free Cash Flow | - | 24.7 | 42.62 | 7.453 |
FCF margin | - | 13.13% | 17.24% | 1.65% |
FCF Conversion (EBITDA) | - | 184.59% | 98.74% | 6.69% |
FCF Conversion (Net income) | - | 240.76% | 125.89% | 8.77% |
Dividend per Share | - | - | - | 0.5000 |
Announcement Date | 13/03/23 | 13/03/23 | 13/03/23 | 29/05/23 |
Balance Sheet Analysis
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | - | - | - | 49 |
Net Cash position 1 | 8.39 | 5.52 | 9.57 | - |
Leverage (Debt/EBITDA) | - | - | - | 0.4404 x |
Free Cash Flow | - | 24.7 | 42.6 | 7.45 |
ROE (net income / shareholders' equity) | - | 40.5% | 71.4% | 66.1% |
ROA (Net income/ Total Assets) | - | 8.89% | 19.3% | 26.4% |
Assets 1 | - | 115.4 | 175.5 | 322 |
Book Value Per Share 2 | 5.050 | 7.620 | 14.80 | 44.10 |
Cash Flow per Share 2 | 3.000 | 2.080 | 2.650 | 7.000 |
Capex 1 | 5.59 | 0.66 | 0.71 | 27.3 |
Capex / Sales | 4.5% | 0.35% | 0.29% | 6.05% |
Announcement Date | 13/03/23 | 13/03/23 | 13/03/23 | 29/05/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+1.91% | 137M | |
+57.45% | 848B | |
+31.64% | 627B | |
-0.73% | 363B | |
+15.06% | 318B | |
+12.07% | 299B | |
+15.45% | 243B | |
+16.70% | 225B | |
+15.72% | 179B | |
+3.42% | 167B |
- Stock Market
- Equities
- REMUS Stock
- Financials Remus Pharmaceuticals Limited